Eurofins: H1 26: Beat on margins, but Biopharma growth turns negative

Research evidence excerpt

Eurofins: H1 26: Beat on margins, but Biopharma growth turns negative

s.

Opinions, estimates and projections constitute the current judgment of the author as of the date of this report. They do not

necessarily reflect the opinions of Deutsche Bank and are subject to change without notice. Deutsche Bank provides liquidity

for buyers and sellers of securities issued by the companies it covers. Deutsche Bank research analysts sometimes have

shorter-term trade ideas that may be inconsistent with Deutsche Bank's existing longer-term ratings. Some trade ideas for

equities are listed as Catalyst Calls on the Research Website (https://research.db.com/Research/) , and can be found on the

general coverage list and also on the covered company's page. A Catalyst Call represents a high-conviction belief by an analyst

that a stock will outperform or underperform the market and/or a specified sector over a time frame of no less than two weeks

and no more than three months. In addition to Catalyst Calls, analysts may occasionally discuss with our clients, and with

Deutsche Bank salespersons and traders, trading strategies or ideas that reference catalysts or events that may have a near-

term or medium-term impact on the market price of the securities discussed in this report, which impact may be directionally

counter to the analysts' current 12-month view of total return or investment return as described herein. Deutsche Bank has

no obligation to update, modify or amend this report or to otherwise notify a recipient thereof if an opinion, forecast or estimate

changes or becomes inaccurate. Coverage and the frequency of changes in market conditions and in both general and

company-specific economic prospects make it difficult to update research at defined intervals.